Prevalence of the Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma Patients from the Middle East Region

Overview

Journal Ann Thorac Med

Specialty Pulmonary Medicine

Date 2019 Jul 24

PMID 31333766

Citations 8

Authors

Arafat Hussein Tfayli

Ghina Bassam Fakhri

Majd Sassine Al Assaad

Affiliations

Soon will be listed here.

Abstract

Lung cancer remains a major cause of cancer mortality with a 5-year survival in advanced stages around 4%. Platinum-based chemotherapy was routinely used as the standard of care in patients with advanced nonsmall cell lung cancer, but it is being progressively replaced by targeted molecular therapy. One of the molecular aberrations harbored by lung adenocarcinoma is the epidermal growth factor receptor (EGFR). A large ethnic variation has been reported in the prevalence of EGFR mutations in patients with lung adenocarcinoma. Data regarding its prevalence from the Middle East area remains limited. This paper aims at reviewing the data available for the prevalence of this mutation in the Middle Eastern patient population and comparing it with other reported series.

Citing Articles

Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer.

Rao D, Huang D, Si M, Lu H, Tang Z, Zhang Z Front Immunol. 2023; 14:1142539.

PMID: 37122754 PMC: 10130367. DOI: 10.3389/fimmu.2023.1142539.

EGFR T751_I759delinsN Mutation in Exon19 Detected by NGS but Not by Real-Time PCR in a Heavily-Treated Patient with NSCLC.

Chang Z, Chan T, Wu C Int J Mol Sci. 2022; 23(21).

PMID: 36362239 PMC: 9654563. DOI: 10.3390/ijms232113451.

Exosomes from -Mutated Adenocarcinoma Induce a Hybrid EMT and MMP9-Dependant Tumor Invasion.

Jouida A, OCallaghan M, Mc Carthy C, Fabre A, Nadarajan P, Keane M Cancers (Basel). 2022; 14(15).

PMID: 35954442 PMC: 9367273. DOI: 10.3390/cancers14153776.

Advances in molecular mechanisms of interaction between and lung cancer: a narrative review.

Xiong K, Sun W, He Y, Fan L Transl Lung Cancer Res. 2021; 10(10):4012-4026.

PMID: 34858788 PMC: 8577982. DOI: 10.21037/tlcr-21-465.

Exosomes: a new perspective in EGFR-mutated lung cancer.

Jouida A, McCarthy C, Fabre A, Keane M Cancer Metastasis Rev. 2021; 40(2):589-601.

PMID: 33855679 PMC: 8213600. DOI: 10.1007/s10555-021-09962-6.

References

Wells A . EGF receptor. Int J Biochem Cell Biol. 1999; 31(6):637-43. DOI: 10.1016/s1357-2725(99)00015-1. View

Weinstein I . Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297(5578):63-4. DOI: 10.1126/science.1073096. View

Giaccone G, Herbst R, Manegold C, Scagliotti G, Rosell R, Miller V . Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol. 2004; 22(5):777-84. DOI: 10.1200/JCO.2004.08.001. View

Herbst R, Giaccone G, Schiller J, Natale R, Miller V, Manegold C . Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol. 2004; 22(5):785-94. DOI: 10.1200/JCO.2004.07.215. View

Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I . EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36):13306-11. PMC: 516528. DOI: 10.1073/pnas.0405220101. View

Razis E, Skarlos D, Briasoulis E, Dimopoulos M, Fountzilas G, Lambropoulos S . Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program. Anticancer Drugs. 2005; 16(2):191-8. DOI: 10.1097/00001813-200502000-00011. View

Amann J, Kalyankrishna S, Massion P, Ohm J, Girard L, Shigematsu H . Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005; 65(1):226-35. View

10.

Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba I . Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97(5):339-46. DOI: 10.1093/jnci/dji055. View

11.

Marchetti A, Felicioni L, Buttitta F . Assessing EGFR mutations. N Engl J Med. 2006; 354(5):526-8. DOI: 10.1056/NEJMc052564. View

12.

Pham D, Kris M, Riely G, Sarkaria I, McDonough T, Chuai S . Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol. 2006; 24(11):1700-4. DOI: 10.1200/JCO.2005.04.3224. View

13.

Al-Kuraya K, Siraj A, Bavi P, Al-Jommah N, Ezzat A, Sheikh S . High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. Hum Pathol. 2006; 37(4):453-7. DOI: 10.1016/j.humpath.2005.12.004. View

14.

De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello M, Aldinucci D . The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 2007; 214(3):559-67. DOI: 10.1002/jcp.21260. View

15.

Kim Y, Kim T, Lee D, Park S, Park J, Seo S . Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer. 2007; 59(1):111-8. DOI: 10.1016/j.lungcan.2007.08.008. View

16.

Weir B, Woo M, Getz G, Perner S, Ding L, Beroukhim R . Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007; 450(7171):893-8. PMC: 2538683. DOI: 10.1038/nature06358. View

17.

Motoi N, Szoke J, Riely G, Seshan V, Kris M, Rusch V . Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008; 32(6):810-27. DOI: 10.1097/PAS.0b013e31815cb162. View

18.

Scagliotti G, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C . Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26(21):3543-51. DOI: 10.1200/JCO.2007.15.0375. View

19.

Herbst R, Heymach J, Lippman S . Lung cancer. N Engl J Med. 2008; 359(13):1367-80. PMC: 10662965. DOI: 10.1056/NEJMra0802714. View

20.

Salim E, Moore M, Al-Lawati J, Al-Sayyad J, Bazawir A, Bener A . Cancer epidemiology and control in the arab world - past, present and future. Asian Pac J Cancer Prev. 2009; 10(1):3-16. View